Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections.
Animals
COVID-19
/ diagnosis
Chemokine CXCL12
/ immunology
Dendritic Cells
/ cytology
Disease Models, Animal
Female
Germany
Humans
Immunity, Innate
Interferons
/ blood
Interleukin-3
/ blood
Lung
/ immunology
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Prospective Studies
Severity of Illness Index
T-Lymphocytes
/ cytology
Viral Load
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
18 02 2021
18 02 2021
Historique:
received:
17
06
2020
accepted:
19
01
2021
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
25
2
2021
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123
Identifiants
pubmed: 33602937
doi: 10.1038/s41467-021-21310-4
pii: 10.1038/s41467-021-21310-4
pmc: PMC7893044
doi:
Substances chimiques
Chemokine CXCL12
0
IL3 protein, human
0
Interleukin-3
0
Interferons
9008-11-1
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1112Références
JCI Insight. 2016 Oct 06;1(16):e87157
pubmed: 27734026
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
J Immunol. 2000 Jan 1;164(1):43-8
pubmed: 10604991
J Immunol. 2011 Feb 15;186(4):2262-72
pubmed: 21242512
Scand J Infect Dis. 1992;24(3):283-92
pubmed: 1324521
J Invest Dermatol. 2010 May;130(5):1337-44
pubmed: 20107485
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Cell Biol. 1997 Mar 10;136(5):1007-21
pubmed: 9060466
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
Intensive Care Med. 2008 Dec;34(12):2202-9
pubmed: 18679655
J Exp Med. 1991 Sep 1;174(3):745-8
pubmed: 1875171
Science. 2015 Mar 13;347(6227):1260-5
pubmed: 25766237
J Immunol. 2020 Jul 15;205(2):307-312
pubmed: 32493814
Blood. 1989 Mar;73(4):945-51
pubmed: 2645952
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
J Clin Invest. 2016 Nov 1;126(11):4187-4204
pubmed: 27721236